Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Disparities in mammogram screening amongst LGBTQ+ populations

Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA

Disparities in mammogram screening amongst LGBTQ+ populations ( Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA )

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers

Dr Marina De Brot - A.C. Camargo Cancer Center, São Paulo, Brazil

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers ( Dr Marina De Brot - A.C. Camargo Cancer Center, São Paulo, Brazil )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2...

Prof Sung-Bae Kim - Asan Medical Center, Seoul, South Korea

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC ( Prof Sung-Bae Kim - Asan Medical Center, Seoul, South Korea )

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy...

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers

Dr Erika P Hamilton - Sarah Cannon Research Institute, Nashville, USA

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers ( Dr Erika P Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Dr Jean Abraham - University of Cambridge, Cambridge, UK

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer ( Dr Jean Abraham - University of Cambridge, Cambridge, UK )

Intraoperative radiotherapy: The Medical City experience

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines

Intraoperative radiotherapy: The Medical City experience ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos

The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )

Boost IORT in breast cancer: Peruvian experience

Dr Gustavo Sarria - INEN, Lima, Peru

Boost IORT in breast cancer: Peruvian experience ( Dr Gustavo Sarria - INEN, Lima, Peru )

More from ecancer